Posted by Michael Wonder on 07 Mar 2022
Rezafungin awarded promising innovation medicine designation by the UK’s Medicines and Healthcare Products Regulatory Agency for the treatment of invasive candidiasis
3 March 2022 - Rezafungin is a next-generation once weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as invasive candidiasis and candidaemia.
Mundipharma and Cidara Therapeutics today announced that the Medicines and Healthcare Products Regulatory Agency in the UK has granted rezafungin promising innovative medicine designation for the treatment of invasive candidiasis.
